Vascular Surgery-Department of Medicine and Surgery, ASST Settelaghi University Teaching Hospital, University of Insubria School of Medicine, Via Guicciardini, 9, 21100, Varese, Italy.
Vascular Surgery-IRCCS Ospedale Maggiore Policlinico Fondazione Cà Granda, Milan, Italy.
Cardiovasc Intervent Radiol. 2021 Feb;44(2):220-229. doi: 10.1007/s00270-020-02676-2. Epub 2020 Oct 19.
To report the outcomes of thoracic endovascular aortic repair (TEVAR) for shaggy thoracic aortic aneurysms (STA).
It is a single center, retrospective, observational, cohort study. Data were collected prospectively between January 2005 and May 2019. STA was defined, based on computed tomography angiography findings, as the presence of an irregular/ulcerated atheroma protruding and/or thrombus thickness ≥ 5 mm protruding into the aortic lumen, and/or occupying more than two thirds of the circumference of the aortic diameter axially. Primary outcomes were early (≤ 30 days) and late survival and freedom from major complication due to end-organ or peripheral ischemic embolization.
Nine (2.3%) of 391 patients met the inclusion criteria. Mean age was 71 years ± 10 (range 55-83). Mean aneurysm diameter was 68 mm ± 0.5 (range 60-75). Four patients presented symptomatic: rupture (n = 2), blue toe syndrome (n = 2). TEVAR was performed in 7 of the 9 patients. Operative-related embolization occurred in 1 patient (transient ischemic attack and acute kidney injury). In-hospital mortality was observed in 1 patient following spinal cord ischemia and multiple organ failure development. Median follow-up was 48 months (IQR 5-84). Freedom from major complication due to end-organ or peripheral ischemic embolization was achieved in all patients. No patient developed further localization of STA in the proximal or distal aorta, and did not experience reno-visceral or peripheral atheroembolization episodes.
Risk of atheroembolism in STA is still threatening but TEVAR proved to be an effective and durable treatment in this high-risk cohort.
报告胸主动脉血管内修复术(TEVAR)治疗毛糙型胸主动脉瘤(STA)的结果。
这是一项单中心、回顾性、观察性队列研究。数据于 2005 年 1 月至 2019 年 5 月期间前瞻性收集。根据计算机断层血管造影(CTA)结果,将 STA 定义为存在不规则/溃疡性粥样斑块突入和/或血栓厚度≥5mm 突入主动脉腔,和/或轴向占据主动脉直径的三分之二以上。主要结果是早期(≤30 天)和晚期存活率以及免于因终末器官或外周缺血性栓塞引起的主要并发症。
391 例患者中,9 例(2.3%)符合纳入标准。平均年龄为 71±10 岁(范围 55-83)。平均瘤径为 68±0.5mm(范围 60-75)。4 例患者出现症状:破裂(n=2),蓝趾综合征(n=2)。7 例患者接受了 TEVAR 治疗。1 例患者发生手术相关栓塞(短暂性脑缺血发作和急性肾损伤)。1 例患者发生脊髓缺血和多器官衰竭,住院期间死亡。中位随访时间为 48 个月(IQR 5-84)。所有患者均免于因终末器官或外周缺血性栓塞引起的主要并发症。无患者近端或远端主动脉出现 STA 进一步定位,也未发生肾-内脏或外周动脉粥样栓塞事件。
STA 的动脉粥样栓塞风险仍然具有威胁性,但 TEVAR 已被证明在这一高危患者群体中是一种有效且持久的治疗方法。